Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Inflammatory Bowel Diseases

  Free Subscription


02.06.2025

1 Aliment Pharmacol Ther
1 Am J Gastroenterol
1 BMC Gastroenterol
2 Clin Gastroenterol Hepatol
1 Gastroenterol Hepatol
1 Gut
1 Hum Pathol
5 Inflamm Bowel Dis
1 J Clin Gastroenterol
3 J Crohns Colitis
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. NARDONE OM, Noor NM, Prabhu A, Lim A, et al
    The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review.
    Aliment Pharmacol Ther. 2025;61:1854-1871.
    PubMed         Abstract available


    Am J Gastroenterol

  2. PAL P
    Listening Beyond the Symptoms: Existential Needs and Identity in Older Adults With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025 May 27. doi: 10.14309/ajg.0000000000003514.
    PubMed        


    BMC Gastroenterol

  3. LI P, Wu Y, Xiong W, Cao J, et al
    Association between the immune-inflammation index and the severity and clinical outcomes of patients with inflammatory bowel disease: a systematic review and meta-analysis.
    BMC Gastroenterol. 2025;25:414.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  4. SINGH S, Poulsen GJ, Bisgaard TH, Bonfils L, et al
    Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study.
    Clin Gastroenterol Hepatol. 2025;23:1204-1215.
    PubMed         Abstract available

  5. CALAFAT M, Kochar B, Ananthakrishnan AN
    A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2025;23:1088-1101.
    PubMed         Abstract available


    Gastroenterol Hepatol

  6. INIESTA-NAVALON C, Rentero-Redondo L, Gomez-Espin R, Saorin MR, et al
    Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes "Infliximab trough levels variability in inflammatory bowel disease".
    Gastroenterol Hepatol. 2025 May 23:502472. doi: 10.1016/j.gastrohep.2025.502472.
    PubMed         Abstract available


    Gut

  7. ALKHATEB O, Ftouni R, Abbas O, Mourad FH, et al
    Skin lesions and chest pain in a patient with Crohn's disease.
    Gut. 2025 May 24:gutjnl-2025-335547. doi: 10.1136/gutjnl-2025-335547.
    PubMed        


    Hum Pathol

  8. CHEN T, Birkness-Gartman JE, Larman TC
    Emerging manifestations of IL-17 immunomodulation in the gastrointestinal tract.
    Hum Pathol. 2025;158:105782.
    PubMed         Abstract available


    Inflamm Bowel Dis

  9. YZET C, Moreau C, Chatelain D, Meudjo E, et al
    Rectal and Rectosigmoid Endoscopy to Assess Endoscopic and Histological Remission in Ulcerative Colitis: A Prospective Study.
    Inflamm Bowel Dis. 2025 May 24:izaf094. doi: 10.1093.
    PubMed         Abstract available

  10. HOU D, Swaminathan A, Borichevsky GM, Frampton CM, et al
    Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 24:izaf110. doi: 10.1093.
    PubMed         Abstract available

  11. BORICHEVSKY GM, Swaminathan A, Smith BR, Edwards TS, et al
    Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 May 24:izaf109. doi: 10.1093.
    PubMed         Abstract available

  12. CHOI D, Kellar A, Klein J, Choi NK, et al
    Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib.
    Inflamm Bowel Dis. 2025 May 24:izaf115. doi: 10.1093.
    PubMed        

  13. BAK MTJ, de Vries AC, Witjes CDM, Arkenbosch JHC, et al
    Intraoperative Autologous Platelet-Rich Stroma Injection as Add-On to Fistula Curettage and Closure of the Internal Orifice Demonstrates a Favorable Outcome in Long-Term in Patients Suffering from Therapy-Refractory Perianal Fistulizing Crohn's Diseas
    Inflamm Bowel Dis. 2025 May 24:izaf011. doi: 10.1093.
    PubMed         Abstract available


    J Clin Gastroenterol

  14. HEGDE Y, Lazarus SK, Farraye FA, Hollnagel F, et al
    High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease.
    J Clin Gastroenterol. 2024 Nov 6. doi: 10.1097/MCG.0000000000002098.
    PubMed         Abstract available


    J Crohns Colitis

  15. VERMEIRE S, Nitcheu J, Gineste P, Flatres A, et al
    Obefazimod in Patients with Moderate-to-Severely Active Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b study.
    J Crohns Colitis. 2025 May 26:jjaf074. doi: 10.1093.
    PubMed         Abstract available

  16. LEHMANN M, Paclik D, Huck A, Arnold A, et al
    Spatial Immune Profiling of Crohn's Disease Fistula Carcinomas - Defining a Distinct Cancer Subtype.
    J Crohns Colitis. 2025 May 26:jjaf086. doi: 10.1093.
    PubMed         Abstract available

  17. SU J, Lartey DA, Zanella G, Hawinkels LJAC, et al
    Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease.
    J Crohns Colitis. 2025 May 24:jjaf087. doi: 10.1093.
    PubMed         Abstract available


    PLoS One

  18. WANG W, Wen Y, Luo J, Miao Y, et al
    Heat shock transcription factor 2 reduces mitochondrial pathway apoptosis in intestinal epithelial cells by inhibiting the increase in mitochondrial membrane permeability in ulcerative colitis.
    PLoS One. 2025;20:e0325275.
    PubMed         Abstract available

  19. SAETERSTAD S, Ostvik AE, Royset ES, Bakke I, et al
    Correction: Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease.
    PLoS One. 2025;20:e0325481.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. OTA N, Davies CW, Kang J, Yan D, et al
    Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling.
    Proc Natl Acad Sci U S A. 2025;122:e2501635122.
    PubMed         Abstract available


    Scand J Gastroenterol

  21. NIELSEN MA, Bendix M, Hvas CL, Deleuran B, et al
    Increased mucosal and T-cell expression of 4-1BB and PD-1 are modulated by anti-TNFalpha treatment in Crohn's disease.
    Scand J Gastroenterol. 2025 May 24:1-9. doi: 10.1080/00365521.2025.2505622.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.